Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

NCT01833520 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01833520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01833520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
October 16, 2013
Completion date
April 8, 2020
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma